SZN-1326, A TETRAVALENT, BISPECIFIC ANTIBODY DEVELOPED FOR THE TREATMENT OF ULCERATIVE COLITIS, HAS A FAVORABLE PROFILE IN 13-WEEK GLP TOXICITY STUDIES

Anh Diep ¹ Jay Tibbitts ¹ Stanley Roberts ² Peter Stathis ² William Nowatzke ² Maureen Newman ² Trudy Vanhove ²
¹ Surrozen, Inc., South San Francisco, United States
² SAR Safety Assessment, Northbrook, United States

Session
IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)

Do you need help setting up your myUEG account?
Contact us at [email protected]

Social Sharing